SCHEMBL16930780

SCHEMBL16930780

NC(=NC=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 1/20 0.51
▸ WDR5 P61964 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ RAB9A P51151 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ CTDSP1 Q9GZU7 1/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GPR52 Q9Y2T5 1/20 0.39
▸ PDCD1 Q15116 1/20 0.39
▸ CD274 Q9NZQ7 1/20 0.39
▸ CDC25B P30305 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16930813 0.80 PARP10 (0.58) SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL16930801 0.76 CYP2D6 (0.48) SMN1; SMN2MAPTKDM4ERAB9ANPC1
SCHEMBL1009423 0.75 GRIN2B (0.58) GRIN2BWDR5SMN1; SMN2MAPTMKNK1
SCHEMBL1009422 0.75 GRIN2B (0.58) GRIN2BWDR5SMN1; SMN2MAPTMKNK1
SCHEMBL14339598 0.74 GRIN2B (0.56) GRIN2BWDR5SMN1; SMN2MAPTMKNK1
SCHEMBL16930783 0.72 KDM1A (0.30) —
SCHEMBL16930799 0.72 TNF (0.50) GRIN2BMAPTRAB9ANPC1MEN1
SCHEMBL16930794 0.72 PARP15 (0.46) MAPTMEN1KMT2AGSK3BL3MBTL1
SCHEMBL16930816 0.70 MAPT (0.55) GRIN2BMAPTRAB9ANPC1MEN1
SCHEMBL16930819 0.70 TSHR (0.56) GRIN2BSMN1; SMN2RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9716235-B2 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl] anthracene compounds, methods of preparing the same, organic electroluminescent devices and organic electroluminescent display apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-07-25 — — US disclosed
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus P2RY10, P2RY4, APRT GRIN2B 2279/4885WDR5 2968/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback